Slide 1: Immatics Corporate Presentation August 17, 2023
Immatics Corporate Presentation August 17, 2023 Exhibit 99.3
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective c
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic Opportunity Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical-Stage Modalities Pipeline of TCR-T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company Intro Differ
Slide 4: Our Near-Term Focus – Clinical Development of Our Lead Assets
Three IMA203 Ph1b cohorts IMA203 monotherapy Checkpoint combo IMA203CD8 monotherapy Next update on all three IMA203 cohorts and clinical development path for PRAME TCR-T monotherapy towards registration-directed trials is planned for 4Q 2023 ACTengine® IMA203 (PRAME) Advance ongoing Phase 1 clinical
Slide 5: Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface
Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface Intro
Slide 6: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR-based Therapeutic Modalities in Clinical Development Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need Intro 1 Interim data update from the ACTengine® IMA203 TCR-T monotherapy Phase 1b Cohort A (published May 02, 2023) with a 64% (7/11)
Slide 7: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Modality Product Candidate Target Preclinical Phase 1a1 Phase 1b1 Phase 2 Phase 3 Autologous ACT ACTengine ® IMA203 PRAME ACTengine® IMA203CD8 PRAME ACTengine® IMA204 COL6A3 Autologous ACT Multiple programs Undisclosed Allogeneic ACT γδ T cells ACTallo® IMA30x Undisclosed Multiple programs Undisclos
Slide 8: Strategic Collaborations
Strategic Collaborations Synergistic Expertise that Can Foster Transformative Innovations for ACT and Bispecifics Research collaboration to develop bispecific immunotherapies 2 Immatics targets $54 M upfront Co-promotion option Broadening the clinical framework beyond our pipeline Research collabora
Slide 9: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers Uterine Carcinoma – 100% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma – 95% Uveal Melanoma1 – 90% Ovarian Carcinoma – 80% Squamous NSCLC – 65% TNBC – 60% Small Cell Lung Cancer – 55% Kidney Carcinoma –
Slide 10: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi-Cancer Opportunity of PRAME ACTengine® IMA203 (TCR-T) and TCER® IMA402 (TCR Bispecific) Indication % PRAME positive patients1 Uterine Carcinoma Uterine Carcinosarcoma Sarcoma Subtypes Cut. Melanoma Uveal Melanoma2 Ovarian Carcinoma Squamous NSCLC TNBC Small Cell Lung Cancer
Slide 11: ACTengine® IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR-T Targeting PRAME
Slide 12: ACTengine® IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR-T Approach IMA203
Slide 13: Key Pillars of Developing a Successful TCR-T Product Candidate
Key Pillars of Developing a Successful TCR-T Product Candidate Summary of Interim Update on IMA203 TCR-T Phase 1b Cohort A as of April 2023 Safety Anti-Tumor Activity Durability Product Quality Broad Reach Manageable tolerability at doses as high as ~9x109 TCR-T cells High rate of objective response
Slide 14: The Multi-Cancer Opportunity of PRAME
The Multi-Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR-based Therapies Known To Date High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof-of-concept sqNSCLC Ovarian Cancer PRAME fulfills all properties of an ideal t
Slide 15: ACTengine® IMA203 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203 TCR-T Monotherapy – Patient Flow HLA-A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow-up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR-T Product Lymphodepletion* Target Profiling Fresh Tumor Biopsy;
Slide 16: ACTengine® IMA203 TCR-T Phase 1b Design
ACTengine® IMA203 TCR-T Phase 1 Design Focus on IMA203 TCR-T Monotherapy Investigated in Cohort A Cohort A Phase 1b Cohort A Interim Update on 11 patients Focus on generation of safety data De-prioritized in the last-line setting, investigation of combination as a front-line therapy being considered
Slide 17: Phase 1b Cohort A Patient and Product Characteristics
N=11 ACTengine® IMA203 TCR-T Monotherapy – Phase 1b Cohort A Patient and Product Characteristics Data cut-off Apr 04, 2023 Heavily pre-treated, metastatic last-line patients that have exhausted all available standard of care treatments 1 Including ovarian cancer patient A-DL5-04 who erroneously rece
Slide 18: Most Frequent Adverse Events – Phase 1b Cohort A
Most Frequent Adverse Events – Phase 1b Cohort A (N=11) Manageable Treatment-emergent Adverse Events (TEAEs) Expected cytopenia (Grade 1-4) associated with lymphodepletion in all patients Low-moderate cytokine release syndrome (CRS) in 91% (10/11) of patients 45% (5/11) of patients had Grade 1 CRS (
Slide 19: Best Overall Response – Phase 1b Cohort A
Best Overall Response – Phase 1b Cohort A Deep Objective Responses Independent of Tumor Type 1 Ovarian cancer patient A-DL5-04 erroneously received one dose of nivolumab and is part of intent-to-treat population (shown here) but not per-protocol population; 2 Initial ORR: Objective response rate acc
Slide 20: Response over Time – Phase 1b Cohort A
Response over Time – Phase 1b Cohort A Durable Partial Responses 9+ Months after IMA203 TCR-T Treatment **Ovarian cancer patient A-DL5-04 erroneously received one dose of nivolumab and is part of intent-to-treat population (shown here) but not per-protocol population; 1 Duration of response (DOR) in
Slide 21: Biological Data Consistent with Clinical Data
Biological Data Consistent with Clinical Data IMA203 TCR-T Levels and Tumor Infiltration across Patients in Phase 1a and Phase 1b Cohort A IMA203 T cells found in all evaluable tumor tissues, level of infiltration associated with objective responses1 Increased levels of IMA203 T cells in the blood o
Slide 22: Favorable TCR-T Product Characteristics and High TCR-T Levels in Patients
Favorable TCR-T Product Characteristics and High TCR-T Levels in Patients Manufacturing Improvements Implemented in Phase 1b Enhance Key Features of the Cell Product Manufacturing success rate of 94% to reach provisional RP2D** Mean cell dose infused in 11 patients in Phase 1b Cohort A was 3.67x109
Slide 23: Responses above Immatics' PRAME RNA Threshold Independent of Tumor Type
Responses above Immatics’ PRAME RNA Threshold Independent of Tumor Type Highlighting Tumor Types (left) and Type of Best Overall Response (right) – Phase 1b Cohort A Mann-Whitney U test, p=0.23; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR: Confirmed Partial Response; NET:
Slide 24: Potential of IMA203 in Additional Solid Cancer Indications
Potential of IMA203 in Additional Solid Cancer Indications Based on PRAME Expression in IMA203 TCR-T Responders – Phase 1b Cohort A Immatics’ proprietary mass spectrometry-guided mRNA threshold 100% 100% 95% 100% 90% (50%2) 80% 60% 65% 25% % PRAME-positive patients1 PRAME target expression distribut
Slide 25: IMA203 TCR-T Monotherapy Summary of Phase 1b Cohort A Interim Data
ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME Summary of Phase 1b Cohort A Interim Data Update Manageable tolerability with no high-grade CRS, no ICANS in 11 patients in Cohort A1 Objective responses observed in heavily pre-treated last-line solid cancer patients including checkpoint-refractor
Slide 26: IMA203 TCR-T Development Strategy
Immatics’ ACTengine® IMA203 TCR-T Development Strategy Two-Pillared Strategy Objective: Expand development to other cancer types Signal finding in other cancer types with a broad patient reach, such as ovarian cancer, uterine cancer, lung cancer, breast cancer, head and neck cancer GO BROAD Next upd
Slide 27: IMA203 TCR-T Product Manufacturing
ACTengine® IMA203 TCR-T Product Manufacturing Enhancing Manufacturing Process and Capabilities Leukapheresis Rapid Manufacturing Process 1 week Expedited QC Release Testing 1 week Infusion-ready Manufacturing of ACTengine® IMA203 TCR-T & other future autologous /allogeneic candidates Expected to be
Slide 28: IMA203 TCR-T Has the Potential to Reach a Large Patient Population
Selected Indications Incidence R/R Incidence PRAME Positive Patient Population Based on R/R Incidence; PRAME and HLA-A*02:01+ Cut. Melanoma 99,800 7,700 95% 2,999 Uveal Melanoma 1,500 800 90% 295 Ovarian Carcinoma 19,900 12,800 80% 4,198 Uterine Carcinoma 62,700 10,700 100% 4,387 Uterine Carcinosarc
Slide 29: ACTengine® IMA203CD8 – Next-generation TCR-T
ACTengine® IMA203CD8 – Next-generation TCR-T Building on First-Gen IMA203 Success to Further Improve Anti-Tumor Activity Engagement of CD4 T cells by CD8 co-transduction reported to boost anti-tumor activity in TCR-T trials Recent data from leukaemia patients treated with CAR-T suggest a relevant ro
Slide 30: IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy
ACTengine® IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy Functional CD4 T cells Mediate Longer Anti-Tumor Activity than CD8 T cells in vitro 2nd addition of tumor cells 3rd 4th 5th 6th 2nd addition of tumor cells 3rd 4th 5th 6th IMA203CD8 Engagement of CD4 T cells may enhance depth and d
Slide 31: ACTengine® IMA204 – TCR-T Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR-T Targeting COL6A3 Exon 6
Slide 32: ACTengine® IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First-in-Class TCR-T Targeting Tumor Stroma Key Features HLA-A*02-presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density1: 100-700 copies/cell Novel tumor stroma target identified and validated by XPRESIDENT® quant. mass s
Slide 33: IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8-independent TCR Complete Tumor Eradication in vitro & in vivo1 by Affinity-enhanced IMA204 TCR CD8-independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 Affinity maturated CD8-independent, next-generation TCR engages b
Slide 34: ACTallo® – Our Next-generation Off-the-shelf TCR-T
ACTallo® – Our Next-generation Off-the-shelf TCR-T
Slide 35: ACTallo® – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ Allogeneic Cell Therapy Approach Off-the-shelf cell therapy, no need for personalized manufacturing à reduced logistics and time to application Potential for hundreds of doses from one single donor leukapheresis à lower cost of goods Use of healthy donor material provides standa
Slide 36: Why γδ T cells?
Why γδ T cells? γδ T cells Are Well Suited for an Off-the-shelf Cell Therapy Approach γδ T cells are abundant in the peripheral blood show intrinsic anti-tumor activity naturally infiltrate solid tumors & correlate with favorable prognosis are HLA-independent, thus do not cause graft-vs-host disease
Slide 37: TCER® — TCR Bispecifics
8oe@ Immatics TCER® — TCR Bispecifics
Slide 38: TCER® – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next-generation, Half-Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements High-affinity TCR domains targeting XPRESIDENT®-selected tumor-specific peptide-HLA molecules Low-affinity T cell recruiter against CD3/TCR Fc part for half-life extension
Slide 39: TCER® – pHLA targeting TCR and T cell recruiting antibody
TCER® – Immatics’ Next-generation, Half-Life Extended Bispecifics pHLA targeting TCR High-affinity (single digit nM) TCR targeting XPRESIDENT®-selected tumor-specific peptide-HLA molecules Broad therapeutic window through XPRESIDENT®-guided affinity maturation (>1000x)1 Complete tumor eradication in
Slide 40: Potency of Our Proprietary TCR Bispecific Format TCER®
Potency of Our Proprietary TCR Bispecific Format TCER® Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody TCER® format had higher combination of potency and specificity1 than six alternative TCR Bispecific format designs evalu
Slide 41: TCER® Format Designed for Optimized Efficacy and Safety: Tumor Control
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low-Affinity Recruiter Widely used T cell recruiting Ab (3 variants) medium to high affinity (single to double digit nM) n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dose: 0.0
Slide 42: TCER® Format: Reduced Recruiter-Mediated Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target-Unrelated Recruiter-Mediated Cytokine Release using a Low-Affinity Recruiter TCER® Whole blood cytokine release assay N=3 HLA-A*02-positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 43: Our TCER® Portfolio
Our TCER® Portfolio Broad Pipeline of Next-Gen Half-Life Extended TCR Bispecifics TCER® PRAME peptide presented by HLA-A*02:01 Start of clinical trial in Aug 2023, first clinical data expected 2024 IMA402 Undisclosed peptide presented by HLA-A*02:01 Preclinical PoC studies ongoing IMA403 Potential f
Slide 44: TCER® IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 Homogeneous Expression, Broad Prevalence and High Copy Number Target MAGEA4 RNA detection in tumor samples (ISH) Indications Target prevalence [%] Squamous non-small cell lung carcinoma 50% Head and neck squamous cell carcinoma 35% Bladder carcinoma 30% Uterine carcin
Slide 45: TCER® IMA401 – Anti-Tumor Activity in vitro
TCER® IMA401 (MAGEA4/8) – Assessment of Anti-Tumor Activity in vitro Patient-Derived Tumor Model NSCLC adenocarcinoma: Male, Caucasian, age 58, no therapy prior to surgery Site of origin: lung, differentiation poor Date of surgery: 1987, Freiburg Medical Center Volume doubling time: 7.3 day Histolog
Slide 46: TCER® IMA401 – Pharmacokinetics
TCER® IMA401 (MAGEA4/8) – Pharmacokinetics PK Analysis in NOG Mice Two different PK assays established to ensure functional integrity of protein domains Terminal half-life in mice: 10-11 days pHLA – VL Assay Fc – VL Assay IMA401
Slide 47: Phase 1 Clinical Trial to Evaluate TCER® IMA401
Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8 MTD: maximum tolerated dose, RP2D: recommended phase 2 dose; MABEL: minimum anticipated biological effect level; BLRM: Bayesian logistic regression model; 1 Pharmacokinetics data assessed throughout the trial might provide an opportu
Slide 48: TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels TCER® IMA402 induces killing of tumor cells with PRAME target copies as low as 50 CpCs Physiological PRAME levels detected in majority of cancer tissues from patients are 100 – 10
Slide 49: TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo
TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo Dose-dependent efficacy of IMA402 in cell line-derived in vivo mouse model Durable shrinkage of large tumors including complete responses over prolonged period Sufficiently high drug doses are key to achieving desired anti-tumor eff
Slide 50: Half-life Extended Format of IMA402
Half-life Extended Format of IMA402 Confers Terminal Half-life of >1 Week pHLA – aVL Assay pHLA – aFc Assay IMA402 shows a terminal serum half-life of ≈ 8 days in mice IMA402 will be initially dosed weekly in the clinical trial Dosing frequency may be adapted based on clinical data IMA402
Slide 51: Phase 1/2 Clinical Trial to Evaluate TCER® IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME First Clinical Data Planned in 2024 Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation Specific indications plus ongoing basket Combination therapies Optional dose/application optim
Slide 52: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ Proprietary Target and TCR Discovery Platforms
Slide 53: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti-Tumor Activity and Minimize Safety Risks of TCR-based Immunotherapies True Targets via XPRESIDENT® technology platform are naturally presented on tumor tissues as identified by mass-spec are absent or presented at only low levels on nor
Slide 54: Pool of Prioritized Targets as Foundation for Future Value Generation
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation 200 Prioritized Targets Grouped in 3 Target Classes: Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens Unknown or poorly characterized parent protein (60%) e.g. stroma target
Slide 55: Identification of the most Relevant Target
Immatics’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 1 Copy number per tumor cell (CpC) measured on a paired-sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.0012 Te
Slide 56: Development of the Right TCR – XCEPTOR® Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo® Fast, efficient and highly sensitive discovery of highly specific, natural TCRs Protein engineering
Slide 57: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De-risking for Clinical Development Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Off-target toxicity
Slide 58: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage Cancer targets, TCRs and technology protected by: 5,800 applications and patents filed in all major countries and regions >115 patent families >2,400 granted patents, thereof >550 granted patents in the US Technology
Slide 59: Corporate Information & Milestones
Corporate Information & Milestones
Slide 60: Management Team
David Leitner Schuldirektor David Leitner Schuldirektor David Leitner Schuldirektor Harpreet Singh Chief Executive Officer Co-Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience (InflaRx, Medigene, NovImmune, Probiodrug) Carsten Reinhardt Chief Developme
Slide 61: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization Houston, Texas ~150 FTEs Cell therapy development & manufacturing Munich, Germany ~65 FTEs Various operating functions Tübingen, Germany ~215 FTEs Target & TCR discovery and TCR Bispecifics development Corporate FTE status as of Decem
Slide 62: Delivering the Power of T cells to Cancer Patients – Appendix
Delivering the Power of T cells to Cancer Patients Appendix www.immatics.com 028 immatics
Slide 63: IMA203 1st Gen Monotherapy Tolerability Data – Cohort A
ACTengine® IMA203 TCR-T 1st Gen Monotherapy Tolerability Data Focus on IMA203 Phase 1b Cohort A – All ≥Grade 3 Adverse Events (N=11) IMA203 was well tolerated No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion No IMA203-rel
Slide 64: Deep & Durable Responses in Heavily Pre-Treated Patients
Deep & Durable Responses in Heavily Pre-Treated Patients – Phase 1b Cohort A Patient ID Indication No of prior treatment lines Prior treatments Total infused dose TCR-T cells1 [x109] BOR BOR (Max % change of target lesions) Comment A-DL5-01 Uveal Melanoma 1 ARRY614/Nivolumab 4.16 cPR -60.3 Ongoing r
Slide 65: IMA203 Tolerability Data Phase 1a and Phase 1b Cohort A
ACTengine® IMA203 TCR-T 1st Gen Monotherapy Tolerability Data Phase 1a and Phase 1b Cohort A – All ≥Grade 3 Adverse Events (N=39) IMA203 was well tolerated No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion No IMA203-relate
Slide 66: Phase 1a and Phase 1b Cohort A – Best Overall Response
Phase 1a and Phase 1b Cohort A – Best Overall Response Confirmed objective responses across a broad spectrum of different tumor types such as cutaneous melanoma, uveal melanoma, head and neck cancer, ovarian cancer, synovial sarcoma * Maximum change of target lesions and RECIST 1.1 BOR at different
Slide 67: Phase 1a and Phase 1b Cohort A – Responses over Time
Phase 1a and Phase 1b Cohort A – Responses over Time Improved Durability at Higher Dose and in Phase 1b Patients Phase 1a (Dose Escalation) N=27# Phase 1b (Cohort A) N=11 Best overall response (RECIST1.1) IMA203 # Synovial sarcoma patient (DL3) PD at week 6 not shown as target lesions were not evalu
Slide 68: Focus on Melanoma Patients
Focus on Melanoma Patients Phase 1a (DL4 only) and Phase 1b Cohort A Continuous Improvement from Phase 1a to Phase 1b Cohort A Patient Characteristics (n=10) IMA203 melanoma patients (n=14) Prior lines of treatment Mean (min, max) 4.5 (1, 7) Previous lines of CPI Mean (Min, Max) 2.6 (1, 4) LDH at ba
Slide 69: Delivering the Power of T cells to Cancer Patients
La a) 7 immatics Delivering the Power of T cells to Cancer Patients www.immatics.com